Max Gelman
Senior Editor at Endpoints News
Reporting on pharma and biotech, @endpts. Baseball fan, Northwestern alum. Email: [email protected]
Articles
-
1 day ago |
endpts.com | Max Gelman
Is Bristol Myers Squibb ready to take on big dealmaking again? When CEO Chris Boerner took over in late 2023, Bristol Myers was in a …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
1 day ago |
endpts.com | Max Gelman
Bristol Myers Squibb’s evolution after sweeping cost-cutting measures kept chugging along as the company reported first-quarter earnings Thursday morning. While overall revenue declined by 6 … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
3 days ago |
endpts.com | Max Gelman
Bristol Myers Squibb’s attempt to turn Cobenfy into a megablockbuster neuroscience drug ran into a stumbling block Tuesday afternoon. The company said Cobenfy, approved last … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
4 days ago |
endpts.com | Max Gelman
Roivant is changing its strategy for Immunovant roughly a month after its subsidiary decided it wouldn’t take one of its drugs to the FDA despite …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
5 days ago |
endpts.com | Max Gelman
The FDA made two decisions on Regeneron’s best-selling drugs Friday, handing down one approval and one rejection. The approval came for Dupixent, the megablockbuster Regeneron … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 2K
- Tweets
- 12K
- DMs Open
- No
Neumora fail: First Phase 3 for depression drug is an unequivocal miss. The company is still running two other identical Phase 3 trials, @ky_lahucik has the latest. $NMRA -79% https://t.co/MFdJpOjqC9
RT @ByLizC: Now updated and with new version of the chart! $NVO $LLY $VKTX $RHHBY https://t.co/t81YXZzq7M
RT @RLCscienceboss: This will be one to watch. Sorriso says it has figured out how to make an orally-administered antibody, and is claiming…